PRECISION MEDICINE: UNLEASHING THE FUTURE OF HEALTHCARE

Abstract

Precision medicine is a healthcare approach that utilizes data from interdisciplinary field of diagnostics, genomics, proteomics, metabolomics, phenotypic characters and data from patients to generate insights to provide tailored therapy for better patient compliance. This chapter focuses on some of the futuristic trends in the field of medicine ranging from the role of pharmaceutical industry in precision health care to the use of pharmacogenomics that studies the genetic variations and the efficacy of therapy provided. The chapter also throws light upon fascinating approaches of futuristic diagnosis techniques that encourages the use of nanotechnology, AI/ML & NLP technologies for complex data analysis and monitoring treatment efficacy. We shall also discuss about Biohacking which objectifies the enhancement of general well-being and promoting lifespan.

Keywords: Precision medicine, pharmacogenomics, futuristic diagnosis, AI/ML & NLP technologies, Biohacking.

Authors

Dr. Kavitha S
Professor
Department of Biochemistry
Sri Venkateswara College of Pharmacy
Chittoor, Andhra Pradesh, India.

N. L. Swathi
Pharm D
Department of Pharmacognosy
Sri Venkateswara College of Pharmacy
Chittoor, Andhra Pradesh, India.

M. S. Riyazullah
Associate Professor
Department of Pharmacognosy
Sri Venkateswara College of Pharmacy
Chittoor, Andhra Pradesh, India

M. Mona Sree
Pharm D
Department of pharmaceutics
Sri Venkateswara College of Pharmacy
Chittoor, Andhra Pradesh, India

Devi Priya
Assistant professor
Department of pharmaceutics
Sri Venkateswara College of Pharmacy
Chittoor, Andhra Pradesh, India

Dr. Achukatla Kumar
Consultant Scientific
ICMR RMRC
Port Blair
Andaman and Nicobar Islands

I. INTRODUCTION

The linkages between biohacking, the pharmaceutical business, genetic medicine, and the chances for diagnosis in the future are examined in this intriguing and instructive chapter. Through the prism of precision medicine, we investigate how these fields are going to impact healthcare in the future. Come along as we set out on a discovery expedition to explore the revolutionary discoveries and improvements that are changing the way we approach diagnosis and treatment.

II. GENOMIC MEDICINE: A PARADIGM SHIFT IN HEALTHCARE

Utilizing genomic data to enhance patient care is the focus of the quickly expanding field of genomic medicine. Since the Human Genome Project's completion, this interdisciplinary medical specialty has expanded quickly. Genomic medicine looks into how using a person's biological data can enhance their clinical care and health outcomes. Using genomic data to find biomarkers that may reflect the expression, function, or control of genes is a multidisciplinary area. In this article, we will look at some of the subtopics of genomic medicine, such as human genetic variation, the economics of genomic medicine, access to genomic medicine, the implementation science approach to genomic medicine, clinical genomics, and public health genomics. A few effects of genomic medicine on health policy will also be discussed.



Figure 1: Precision medicine timeline

III. HUMAN GENETIC VARIATION

The term "human genetic variation" describes the variations in DNA sequence seen inside the genomes of people living in groups. Single nucleotide alterations or substitutions, tandem repeats, insertions and deletions (indels), copy number variations (CNVs), and more are all examples of genetic variants. The most frequent sort of genetic variation, known as a single nucleotide polymorphism (SNP), occurs about 1 in every 400 bases of the DNA sequence. The start of the 1000 Genomes Project, which seeks to create the most complete map of genetic variants in the human genome, shows that research into genetic variations is receiving a lot of attention and effort from the genetics field. The evolution of human genetic diversity has significant medical ramifications, especially in the fields of precision medicine and pharmacogenomics. Pharmacogenomics is the study of how a patient's reaction to medication is influenced by genetic differences.

Genetic variations can change how drugs are metabolised, transported, and targeted, which can change how effective and toxic they are. Precision medicine is a method of treating patients that considers the individual variability in each person's genes, environment, and lifestyle. Healthcare professionals can better treat patients and achieve better results by recognising each person's unique genetic variations. The evolution of human genetic diversity has significant medical ramifications, especially in the fields of precision medicine and pharmacogenomics. Pharmacogenomics is the study of how a patient's reaction to medication is influenced by genetic differences. Genetic variations can change how drugs are metabolised, transported, and targeted, which can change how effective and toxic they are. Precision medicine is a method of treating patients that considers the individual variability in each person's genes, environment, and lifestyle.

Healthcare professionals can better treat patients and achieve better results by recognising each person's unique genetic variations. The evolution of human genetic diversity has significant medical ramifications, especially in the fields of precision medicine and pharmacogenomics. Pharmacogenomics is the study of how a patient's reaction to medication is influenced by genetic differences. Genetic variations can change how drugs are metabolised, transported, and targeted, which can change how effective and toxic they are. Precision medicine is a method of treating patients that considers the individual variability in each person's genes, environment, and lifestyle. Healthcare professionals can better treat patients and achieve better results by recognising each person's unique genetic variations.

IV. ECONOMICS OF GENOMIC MEDICINE

The cost-effectiveness of genetic testing and the effect of genomic medicine on healthcare delivery are key aspects of the economics of genomic medicine, which is a complicated subject. By condensing genetic testing to a single analysis, which then informs people throughout their lives, the use of genomic information in medicine has the potential to make genetic diagnosis of disease a more effective and affordable process. Its widespread adoption, however, may be hampered by the expense of genomic testing and the infrastructure needed to support it. The cost-effectiveness of genetic testing and the effect of genomic medicine on healthcare delivery are key aspects of the economics of genomic medicine, which is a complicated subject. By condensing genetic testing to a single analysis, which then informs people throughout their lives, the use of genomic information in medicine has the potential to make genetic diagnosis of disease a more effective and affordable process. Its widespread adoption, however, may be hampered by the expense of genomic testing and the infrastructure needed to support it.

Despite these difficulties, there are substantial potential financial gains from genomic medicine. Benefits to one's personal finances may result from genomically informed health restoration and subsequent increases in earning capacity. By avoiding negative effects and unnecessary treatments, higher precision in risk identification lowers health costs for a person and the healthcare system. The national economy will also be significantly impacted by

genomic medicine. The country's economy will be significantly impacted by the use of genomic data in technological advancements, medical research, and healthcare.
The utilisation of genetic data in medicine has substantial implications for healthcare delivery in addition to the economic advantages. By enabling more individualised and targeted therapies, the incorporation of genetic data into clinical care offers the potential to enhance patient outcomes and lower healthcare costs.

V. ACCESS TO GENOMIC MEDICINE

Access to genomic medicine is an important topic that involves ensuring equitable access to genomic medicine, including the role of health systems in delivering genomic medicine and ways in which providers can make genomic medicine more accessible to underserved populations.

Table 1: An overview on Genomic medicine

Content	Description
Definition of Genomic Medicine	According to the definition of genomic medicine, this discipline employs genetic data to direct therapy and diagnosis choices. It aims to understand how an individual's unique genetic makeup influences their health and disease risk.
Advancements in Genomic Medicine	Recent advancements in genomic medicine, including new sequencing technologies, have revolutionized the field. These advancements have enabled faster and more accurate diagnosis, personalized treatments, and precision medicine.
Electronic Health Records and Genomic Medicine	The readiness of electronic health records for genomic medicine is discussed, along with challenges that need to be addressed. Integrating genomic data into electronic health records is essential for leveraging genetic information in clinical settings.
Content Types in Genomic Medicine	Various content types in genomic medicine, such as research articles, figures, and tables, play a crucial role in communicating research findings and promoting knowledge dissemination within the scientific community.
Continuing Education in Genomic Medicine	The need of continuing education in genomic medicine is stressed since it is essential for healthcare professionals to keep current with emerging genetic technology in order to deliver high-quality patient care and make educated decisions. Topics such as bioinformatics, interpretation of genetic data, and ethical considerations are essential for readiness to practice genomic medicine.
Impact of Genomic Medicine	The potential impact of genomic medicine on healthcare is highlighted, particularly in rare diseases, pharmacogenetics, and cancer. Genomic insights offer targeted therapies, early detection, and personalized treatments, improving patient outcomes.
Challenges in Genomic Medicine	Challenges in genomic medicine, such as ensuring comprehensive education in foundational concepts and practical skills, are mentioned. To exploit the advantages of genomic medicine and enhance patient care, these issues must be resolved.

The expense of genetic testing and the infrastructure needed to support it is one of the major barriers to obtaining genomic medicine. The price of genetic testing may prevent it from being widely used, especially in poor areas where access to resources may be limited. Access to genomic medicine may be made more difficult by additional ethical, legal, and societal issues surrounding the use of genetic data.

There is a need for more education and understanding regarding genomic medicine among healthcare professionals and the general public in order to solve these issues. This may assist to lessen the stigma attached to genetic testing and raise demand for services in genomic medicine. In addition, there is a need for increased funding for research and development in genomic medicine, particularly in the areas of pharmacogenomics and precision medicine

Another important aspect of improving access to genomic medicine is the role of health systems in delivering genomic medicine. Health systems can play a critical role in ensuring equitable access to genomic medicine by providing education giving instruction to healthcare professionals, creating regulations and standards for the application of genetic data in clinical treatment, and putting money into the infrastructure required to enable genomic testing and analysis. There are also opportunities for healthcare providers to make genomic medicine more accessible to underserved populations. This can include developing culturally appropriate educational materials, partnering with community organizations to provide outreach and education, and offering genetic counselling services to help patients understand the implications of genomic testing

VI. APPLICATION-BASED SCIENTIFIC APPROACH TO GENOMIC MEDICINE

The study of strategies to encourage the adoption and integration of evidence-based procedures, treatments, and policies into everyday practise as well as to raise the standard and efficacy of healthcare services is known as implementation science.
By analysing how healthcare providers and organisations behave and then using that information to change standard clinical practise, implementation science can speed up the translation of fundamental and clinical genetic research discoveries in the field of genomic medicine.

Multiple translational phases of research can involve implementation science to help further the use of genomics in practical situations. It is still unclear, nevertheless, how much implementation science methods are included in translational research in genetic medicine. In order to secure the community benefit of genomic medicine, more study is required to determine the extent to which implementation science is included in studies on the subject. The adoption and integration of genomic medicine into standard clinical practise can be facilitated by the use of rigorous implementation science methodologies rooted in theory and practise.

VII. CLINICAL GENOMICS

Clinical genomics is an area of study that examines how variations in our genomes affect our health and the creation of novel drugs based on genetic data. It is a multidisciplinary discipline that uses genetic data to find biomarkers that can indicate how genes are expressed, function, or are regulated.

Clinical genomics has significant medical ramifications, especially in the fields of precision medicine and pharmacogenomics. Pharmacogenomics is the study of how a person's reaction to medication is influenced by genetic differences. Genetic variants can influence how medications are metabolised, transported, and targeted, resulting in changes in the effectiveness and toxicity of pharmaceuticals.

Precision medicine is a method of treating patients that considers the unique diversity in each person's genes, environment, and lifestyle. Healthcare professionals can better treat patients and achieve better results by recognising each person's unique genetic variations.



Figure 2: Omics and Personalized medicine data integration in human body

New methods of developing therapeutics, providing healthcare, and managing population health have also been developed as a result of the use of clinical genomics. For instance, the utilisation of genetic data can assist in identifying people who are more likely to contract particular diseases, enabling earlier intervention and prevention.

But there are drawbacks to using clinical genomics, such as the expense of genetic testing and the infrastructure needed to support it. The application of clinical genomics can be complicated further by the ethical, legal, and societal issues surrounding the use of genetic data.

VIII. PUBLIC HEALTH GENOMICS

In the developing field of public health genomics, the effects of genes and how they interact with behaviour, food, and the environment to affect population health are evaluated. It is the use of developments in molecular biotechnology and human genetics to enhance public health and avoid illness. Public health genomics focuses on the efficient and ethical application of genetic knowledge to improve population health. Health policy is significantly impacted by the use of genetic data in public health. The promise for genomic technology to change public health has been at the forefront of applications in clinical care. The use of genetic data in public health can aid in identifying those who have a higher risk of contracting particular diseases, enabling earlier intervention and prevention.

IX. IMPLICATIONS OF GENOMIC MEDICINE FOR HEALTH POLICY

The ethical, legal, and social issues surrounding the use of genetic data in public health are one of the key obstacles to overcome. These worries may relate to difficulties with confidentiality, discrimination, and privacy. Additionally, there is a need for more healthcare professionals and members of the general public to get education and understanding of genomic medicine in order to lessen the stigma attached to genetic testing and boost demand for genomic medicine services. Increasing financing for public health genomics research and development is necessary to meet these challenges, especially in the fields of pharmacogenomics and precision medicine.

In addition, there is a need to create the infrastructure needed to facilitate genetic testing and analysis as well as rules and standards for the use of genomic data in public health. Precision public health, an emerging interdisciplinary discipline that integrates genomes, big data, and machine learning/artificial intelligence to anticipate health risks and outcomes and to enhance health at the population level, is significantly impacted by the application of public health genomics. Precision public health has the potential to transform public health by enabling more targeted and personalized interventions, leading to improved health outcomes and reduced healthcare costs.

The field of public health genomics is crucial to the research of genomic medicine. It is possible to increase population health and prevent disease by using genetic data in public health. However, there are issues with the use of genetic data, including moral, societal, and legal issues. To fully comprehend the implications of public health genetics for health policy and to provide practical methods for implementing this knowledge into public health practise, more study is required.

X. BIOHACKING: EMPOWERING INDIVIDUALS IN THE PURSUIT OF HEALTH

Biohacking, sometimes referred to as human augmentation or human enhancement, is a process in which people customise their approach to health and wellbeing in order to improve their physical and mental performance. It combines scientific methods for food, exercise, and lifestyle adjustments with the use of technology and self-experimentation to improve physical and mental capabilities.

Biohacking is centred on the idea of self-improvement and optimization, with people attempting to reach their full potential through experimentation and technological use. It includes a variety of behaviours such as monitoring and analysing data about one's own health, making gradual adjustments to one's physical appearance, nutrition, and lifestyle, and leveraging technology to improve performance. The emergence of citizen science, technological breakthroughs, and growing public interest in individualised health and wellbeing are some of the reasons that came together to give rise to biohacking.

The proliferation of wearable technology, such fitness trackers and smartwatches, has given people the capacity to track and monitor numerous health data in real-time.The spread and acceptance of biohacking have been facilitated by this, as well as the availability of knowledge and the capacity to interact with like-minded people through online forums. The use of wearable technology and intermittent fasting are two very safe and widespread examples of biohacking activities. Genetic engineering and blood transfusions are two more experimental but less widespread examples. Despite the fact that certain biohacking techniques may be advantageous, others may pose health hazards and should be used with caution.

XI. TYPES OF BIOHACKING



How Biohacking Aligns with the Precision Medicine

Aspect	Biohacking	Precision Medicine
Definition	The term "biohacking" describes a popular movement where people experiment on themselves to improve their health and well-being using technology and scientific knowledge.	Precision medicine is a new medical strategy that involves customising medical therapies based on a patient's particular genetic make-up, way of life, and clinical data to produce the best therapeutic results.
Approach	Personalized optimization is the goal of biohacking, which is motivated by people' own decisions and activities.	The development of individualised methods is based on substantial clinical research, data analysis, and best practises.
Genetic Emphasis	Individual genetic variances are highlighted by biohacking, which concentrates on comprehending and utilising genetic data for the improvement of one's health and performance.	The use of genetic profiles to inform treatment choices and forecast disease risks are all important components of precision medicine.
Therapeutic Goals	Enhancing general well-being, maximising physical and mental performance, and promoting lifespan are the main objectives of biohacking.	Precision medicine offers customised therapies based on the unique features of each patient in an effort to increase therapeutic effectiveness, safety, and results.

Integration of Data	In order to make well-informed judgments about health interventions, biohacking frequently combines self-collected data from lifestyle, dietary, and biometric sources.	In order to create a thorough patient profile, precision medicine entails the integration of several datasets, including genetic, clinical, environmental, and lifestyle data.
Personal Empowerment	By empowering people to actively participate in their health decisions, biohacking empowers people to take charge of their wellbeing.	By include patients in the decision-making process, giving them access to individualised treatment alternatives, and educating them about their options, precision medicine empowers patients.
Customization	Biohacking is characterised by customization, with treatments made to fit each person's tastes and objectives in order to achieve personal optimum.	In precision medicine, where therapies are individualised based on genetic, clinical, and lifestyle characteristics, a patient-centric approach is guaranteed, customization is a fundamental concept.
Disease Prevention	The focus of biohacking is on proactive lifestyle changes that improve general health and sickness prevention.	In order to allow preventative measures, precision medicine focuses on early illness identification and management, identifying risk factors based on genetic susceptibilities.

XII. FUTURE PROSPECTS OF DIAGNOSING: UNLOCKING NEW FRONTIERS

Medical condition diagnosis is a discipline that is constantly evolving due to technological breakthroughs and novel methods. The ability to identify illnesses more accurately in the future will allow for earlier identification, individualised treatment programmes, and more accurate evaluations. With an emphasis on the use of artificial intelligence (AI), nanotechnology, and other upcoming technologies, we will examine the fascinating potential that lie ahead in the field of diagnosis in this introduction.
AI may be applied in a variety of areas to advance human welfare and development, including the clinical sphere, where it can help medical practitioners with diagnosis, identifying disease features, therapy, prognosis, prevalence, and research.
Currently, there are five uses for AI :

- Assessing disease severity
- Predicting treatment efficacy
- Preventing complications
- Assistive technology
- Analysing enormous data

AI/ML can be used in liquid biopsy for cancer detection, identify disease causing genomic variants, to predict future variants of existing pathogens genome, and to improve gene editing process and tools by means of deep learning (a form of AI).

1. **Rare Diseases:** Rare diseases are a condition with low prevalence and that affects a small number of the population compared with other prevalent diseases. Classical diagnosis of such diseases is time consuming, challenging and in some cases misdiagnosed especially if the patient presents with atypical symptoms and these conditions have a large phenotypic spectrum.

2. **Use of AI:** Data driven architecture can be utilised for storing patient details and also enables the collection, integration and analysis of various data sources such as Electronic Health Records, scientific documents, literatures for phenotyping rare conditions. Many types of AI tools are used in the healthcare system for diagnosis of rare diseases. Computer vision is one such AI technique. By obtaining, processing, analysing, and comprehending digital pictures, computer vision is a branch of artificial intelligence that enables computer systems to extract information from digital images like x-rays and other visual inputs.

XIII. NLP [NATURAL LANGUAGE PROCESSING]

The relationship between human and computer language is the focus of the field of AI known as natural language processing. It is used to extract information from free, unstructured texts like patient narratives and clinical notes. It helps physicians to identify specific phenotypic traits, medical information, and the genetic condition of a patient.

Figure 3: An illustrative diagram on futuristic diagnosis and treatment on patient bedside

NLP can process vast amounts of textual data; it can be combined with data-driven architecture to enhance the efficiency of phenotyping by reducing manual efforts and accelerates the potential diagnosis process. The technique can also be used to analyse vast amounts of scientific documents, literature, analyse case reports, research documents, genetic markers for accurate diagnosis and for designing a personalized treatment plan.
NLP in healthcare is an interdisciplinary field which utilises the applications of NLP in the medical sector. This can also be used in clinical trials, EHRs, literatures, information extraction process, machine learning based text mining and medical knowledge graph construction.

Therefore, leveraging this technology helps the patients to reduce Diagnostic delay, financial burden to provide early interventions and appropriate therapy to improve their quality of life and better health outcome.

XIV. ADVANCES IN CANCER DIAGNOSIS

The diagnosis and treatment are a challenge for clinicians. Recent advancement of non-invasive methods of diagnosis (CTCs), cancer associated mutations, cell free DNA , micro RNA, in biological fluids such as blood, CSF, urine. CTCs are initially shed by primary tumors that accounts for the development of metastatic tumors. Circulating tumour DNA from extravascular vesicles are membrane bound that consist of nucleic acid proteins, circulating cell free RNA, small RNA etc. For pathologists, this offers thorough information on both primary and metastatic tumours. CTCs can be used to measure therapy response and tumour staging, with a lower count indicating a better prognosis.



Figure 4: Liquid biopsy used to analyse substances isolated from blood where each analyte helps in tumor diagnosis.

In order to identify live CTCs, the EPISPOT (Epithelial ImmunoSPOT) test employs membrane-bound antibodies directed against the epithelial cell adhesion molecules (EpCAM or CD326) on tumour cells. Adna test is a different examination that uses PCR to identify tumor-specific mRNA transcripts.

This provides accurate information about tumour characteristics and early detection compared to traditional tissue biopsies. Thereby significantly enhancing patient outcome and potentially helps in preventing cancer from advancing to later stages.

Liquid biopsy can also be used in treatment monitoring by analysing tumour heterogeneity, genetic alterations and to find therapeutic targets to prompt treatment response providing tailored therapy and helps in periodic monitoring to detect emergence of drug resistance or treatment resistance for adapting new treatment regimens and timely treatment modifications to improve patient outcome and reduces unnecessary procedures.
Moreover, advances in AI/ML are being leveraged to expand algorithms for accurate interpretation of complex data generated by liquid biopsy.

XV. MI DETECTION

Myocardial Infarction also called as heart attack is caused due to decreased blood flow to the myocardium of heart leading to sudden death. Road accidents due to emergency medical conditions such as MI in drivers are increasing overtime. Researchers are developing wearable real time MI detection systems for road safety.

The device can be a smart watch or a chest strap that utilizes advanced sensors interlaced within them and analyses the sensory data via AI/ML algorithms which monitors vital signs of blood pressure, heart rate, ECG signals to detect abnormal signs of heart attack.

Table 2 : Overview on use of AI in various health departments

Healthcare Department	Future Aspects of Diagnosing
Cardiology	Advanced wearable devices for continuous heart monitoring
	AI-based algorithms for early detection of heart diseases
	Genomic testing to identify genetic risks for heart conditions
Oncology	**Non-invasive imaging techniques for precise diagnosis**
	Liquid biopsies for early cancer detection and monitoring
	Personalized cancer vaccines tailored to individual genomes
	AI-driven predictive analytics for treatment outcomes
Neurology	**Nanotechnology for targeted drug delivery**
	Brain-computer interfaces for improved diagnosis
	Genomic profiling for personalized treatment plans
	Biomarkers for early detection of neurodegenerative diseases
Rheumatology	**Virtual reality-based diagnostic tools for neurological conditions**
	Advanced imaging techniques for accurate joint assessment
	Biomarker-based tests for early detection of autoimmune diseases
	AI-powered algorithms for predicting disease progression
Gastroenterology	**Precision therapies targeting specific immune system components**
	Non-invasive methods for diagnosing gastrointestinal diseases
	Genomic testing for personalized treatment regimens
	AI-driven analysis of gut microbiome for disease association
	Wireless capsule endoscopy for comprehensive intestinal examination

Pulmonology	AI-powered lung function tests for early disease detection
	Genomic profiling for targeted therapies in lung diseases
	Wearable devices for continuous respiratory monitoring
	Virtual reality-based pulmonary simulations for training

Upon detection of abnormality the device sends warning alerts as auditory signals, visual signals, and high vibration patterns. Furthermore, this also informs the emergency medical services along with the driver's location for immediate medical assistance.
The device can also be integrated with vehicle systems by connecting to the vehicle’s onboard computer to collect additional information of driving pattern, steering wheel movement and to monitor driver’s condition such as head position, eye movement, posture and gestures to provide timely warning of any possible cardiac events.
The data collected from the device can also be analysed by the physicians to identify possible risks, aggregating factors and implement targeted interventions. To prevent unauthorised access the device adheres to privacy and strict security.

XVI. RECENT TRENDS IN PRENATAL TESTING AND SCREENING

Prenatal testing and screening or used to identify genetic birth defects in foetus. The major advancement is the development of non-invasive prenatal testing (NIPT) employing bioinformatics and epigenetics involves testing for common chromosomal abnormalities such as Edwards syndrome by analysing cell free DNA present in maternal blood. High resolution analysis of foetal nucleated RBC and trophoblasts in maternal circulation also helps to detect abnormalities.

Recent trends have paved a way for expanded screening panels which unlike traditional screening, focuses on a broad range of genetic conditions including single gene defects, intellectual disabilities thereby enabling the clinicians to recognise potential risks and offer management strategies.

The examination of foetal cells from maternal circulation is made possible by developments in single cell genomics. Individual foetal cells may be isolated from the mother's blood, and foetal DNA can be examined to look for chromosomal abnormalities. By looking at the foetal genome at a greater resolution, the accuracy can be improved and it can assist identify micro delusion syndrome. By using a silicon-based, nanostructured, microfluidic platform with antibody coatings that bind to specific antigens on the surface of circulating, foetal nucleated RBC, it is possible to separate foetal cells from maternal blood.

For a foetus to develop normally throughout pregnancy, the placenta is crucial. By regulating splicing, activating or repressing genes, and other epigenetically regulated processes, DNA methylation plays a critical role in the functioning and development of the placenta. The placenta's DNA methylation process may be faulty, which might result in the production of aberrant genes that have an impact on embryonic development. By treating the DNA with sodium bisulfite, which results in the formation of unmethylated cytosine, the DNA methylation status can be ascertained. Bisulfite sequencing distinguishes cfDNA produced from foetal tissues from cfDNA obtained from tumours because various tissues show changes in the methylation process. Methy-pipe is a bioinformatics tool for downstream methylation, sequence alignment, and data preparation that is used to analyse data from whole genome bisulfite sequencing. When there is a methy-pipe, it can be difficult to get a high resolution image of the placental methylome. FEMER (foetal methylome reconstructor) can be useful in these situations



Figure 5 : Nanostructured microfluidic immunoassay platform

Prenatal ultrasound diagnosis plays an important role during pregnancy. Repeated ultrasound diagnosis helps to detect congenital abnormalities in the growing foetus. However, factors such as foetal mobility abdominal wall thickness of the pregnant mother etc makes ultrasound challenging on gradual implementation of deep learning into this ultrasound diagnosis not only helps to minimise time and manual workload but also helps in appropriate diagnosis of foetal growth abnormalities, measurements of head circumference, gestational age and weight assessment enables to target minimising foetal mortality and morbidity rates.

XVII. DERMAL TATTOO DIAGNOSTICS

Tattoos are a kind of body art imprinted on skin. Innovations in the medical field have paved the way to colorimetric dermal tattoos as a biosensor that involves change in its characteristics due to alterations in the biomarkers such as pH, uric acid, temperature, glucose which can be read by naked eyes. These quantitative changes in biomarkers can be detected for 4 days thus can be helpful in monitoring long-term conditions.



Figure 6: Colorimetric dermal tattoo detection of A) & B) ex vivo glucose concentration, body temperature respectively and Hue values C) & D) as a function of glucose concentration and temperature extracted from previous images.

By substituting colorimetric sensing reagents for typical tattoo inks and forming the biosensors under the stratum corneum, a robust physical barrier against perspiration and other outside influences is created.

XVIII. MOLECULAR DIAGNOSTICS

Molecular diagnostics is a combination of techniques that involves analysis of DNA, RNA and proteins to identify disease. It includes PCR, Real-time polymerase chain reaction, multiplex polymerase chain reaction, ELISA, immunoassay, genetic testing, whole-exome sequencing, DNA microarray etc.

dPCR digital polymerase chain reaction is highly sensitive and can be used to detect low levels of pathogen targets and minor mutations. Used for quantification of low microorganisms content such as HIV (Human Immunodeficiency Virus), HRV(Human Rhinovirus). The technique performs absolute quantification of the target genes where the amplification reactions are divided into thousand sectors by using microarrays, microplates into separate compartments. Based on the fluorescence threshold, the droplets generated are identified as positive and negative whose ratio helps to calculate target gene content. To attain accurate quantification, proper threshold setting is very important as this can be affected by many factors such as length of probe, primer factors, sample's quality and quantity.

A novel molecular diagnostic method called HRM (High Resolution Melting) is based on variations in the melting points of various ds-DNA. The technique is quick and affordable for genotyping and identifying species. Pathogens are found by tracking changes in the melting curve's form with fluorescent probes. In the identification of Candida spp., Aspergillus spp., and Cryptococcus spp., this approach demonstrated great sensitivity and specificity, permitting early diagnosis.

Microarray analysis has gained prominence in prenatal genetic testing. This technique allows for the detection of chromosomal abnormalities and the identification of sub microscopic deletions or duplications in the foetal genome.

1. **Microarray analysis** provides a higher resolution compared to traditional karyotyping, enabling the detection of smaller genetic imbalances associated with developmental disorders. It has become an integral part of the diagnostic workup for individuals with congenital anomalies detected during prenatal ultrasound.

2. **Whole -Exome Sequencing (WES):** Exome is part of the genome consisting of exons. WES is a genomic technique of sequencing protein coding regions of the gene. This can analyse any abnormalities and detect the presence of mutations in genetic impairments.



Figure 7 : Colorimetric dermal tattoo detection of A) & B) ex vivo glucose concentration, body temperature respectively and Hue values C) & D) as a function of glucose concentration and temperature extracted from previous images.

3. **Biosensing** is a new molecular diagnostic that enables the combination of target biomarker and ionic conductivity materials to generate signals that can be detected by optical or electrochemical sensors. An example is the use of photoelectric biosensing of the genome for diagnosis and quantitative analysis of infectious diseases. Further studies revealed the use of such biosensors in identifying mycobacterial proteins and interferons in early detection of tuberculosis.

4. **Fluorescence in situ hybridization (FISH)** detects specific nucleic acid sequence in a cell can be combined with flow cytometry to detect in thousands of cells separately. Hence integrating their use in bacterial identification, monitoring pathogen growth, detecting infected cell growth, gene expression etc.

   In cases of secondary antibiotic resistance due to empirical treatment before the test results, molecular diagnostics produces quicker results compared to classical tests thereby timely screening and detection of resistance makes the method an integral part of diagnosis.

   Combining the studies of pharmacogenomics and precision medicine with molecular diagnostics paves way for a new era in the healthcare system.

XIX. PRECISION MEDICINE AND METABOLOMICS

Metabolomics is a scientific study of metabolites (end products of biological processes) in our body which includes amino acids, carbohydrates, lipids, bile acids etc. It was found that disease states alters the metabolite status that can be used to understand physiology of the disease and can be used as biomarkers for disease identification.

A biomarker is characterised as "a trait that is reliably tested and assessed as an indication of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention," according to the National Institutes of Health. Blood, lymph, urine, and saliva are examples of bodily fluids that may include biomarkers that may be analysed to find certain medical diseases. By combining artificial intelligence and machine learning, medical diagnosis in this rapidly developing technological era may become accurate and speed up the discovery of biomarkers for precise therapy.



Figure 8 : Impact of Whole – Exome Sequencing on public health.
(PND- Prenatal diagnosis
PGD- Pre implementation genetic diagnosis)

Metabolomics focuses on identification and quantification of metabolites in the physiological fluids and provides details of metabolic status, treatment responses, monitoring disease progression and alterations of metabolites during diseased conditions such as metabolic disorders, cardiovascular diseases, cancer etc. Thereby helping the physicians to analyse the metabolomic profile for choosing optimal therapeutic options and drug dosage regimen to minimise unwanted adverse effects.

The samples can be analysed using mass spectrometry (MS) and nuclear magnetic resonance (NMR) technologies. NMR provides superior repeatability than MS technology, however MS-based metabolomic technology is frequently employed in clinical research because of its higher sample size requirements and poorer sensitivity.

In-vitro metabolite detection is accomplished using MS-based methods, while in-vivo metabolite detection and visualisation are accomplished using imaging mass spectrometry (IMS). This is used to examine the endogenous metabolites' spatial distribution inside the tissue. For a larger metabolite coverage and quicker scans, matrix assisted laser desorption ionisation (MALDI) IMS is now the most used commercial IMS mode. In order to diagnose colon cancer, this method has been combined with MRI (Magnetic Resonance Imaging).

Pharmacometabolomics is the new branch of metabolomics that studies the efficacy of drug therapy by identifying the biomarkers associated with specific organ's response to the treatment, further helps to plan an effective dosage regimen as a part of Therapeutic Drug Monitoring (TDM) and to monitor body's response to drug, external factors, drug interactions and toxicity of the drugs.

However the requirement of robust bioinformatic tools and sophisticated analytical techniques for data interpretation and complexity of data reproducibility issues and other important issues, integration with other technologies poses limitations in the metabolomics technology.

XX. THE ROLE OF PHARMACEUTICAL INDUSTRY IN PRECISION MEDICINE

One of the sectors with the quickest rate of growth worldwide is the pharmaceutical sector, which demands ongoing innovation. The pharmaceutical industry has been incorporating precision medicine in their drug development pipeline to generate unprecedented insight into the genetics of human disease and a wealth of novel drug targets and biomarkers. However , there are unique challenges in the precision medicine pipeline, including ethical considerations, regulatory challenges, and limitations of current technologies. Despite these challenges, precision medicine holds immense promise as a facilitator of more targeted therapies and a healthier society.

Despite their expansion, pharmaceuticals still have a number of challenges to overcome if they are to be successful and remain competitive in a market that is always evolving. The pharmaceutical sector is clearly shown in recent statistics, which also highlights both its influence and its challenges.

Industry forecasts predict that by 2023, global pharmaceutical sales would surpass $1.5 trillion, reflecting the rising need for healthcare solutions globally.
By examining present patterns and future projections in the pharmaceuticals industry, the pharmaceutical business is anticipated to witness a transition from traditional sales positions to medical affairs responsibilities in 2023. Real-world evidence, the revolution in organs-on-a-chip, and health economics research are examples of emerging trends. Synthetic data and AI-based medications are gaining popularity, and health sciences firms will increasingly value the human touch. The worldwide pharmaceutical industry saw strong growth, increasing slightly from 2021 to 2022 to reach 1.48 trillion US dollars.

XXI. CONCLUSION

Finally, "Converging Horizons" displays a breathtaking work of art that alters the face of healthcare. The complex relationships between biohacking, the pharmaceutical business, genetic medicine, and future diagnostics paint an alluring picture of individualised treatment, tailored medicines, and ground-breaking developments. It is clear that this synergistic interaction is changing medicine as we know it as we stand at the beginning of this revolutionary age.

Biohacking's emergence in the healthcare industry demonstrates a dynamic trend toward individualised therapy. Biohacking encourages patients to actively participate in their health journey by embracing unique genetic differences and utilising cutting-edge technology, transforming them into partners rather than passive recipients of treatment. This recently formed cooperation opens the way to painstakingly individualised treatments and therapies that take into account the distinctive genetic profiles of each individual.
Using genomic medicine, we can decipher the secrets contained in our DNA. It may be possible to create medicines that specifically target genetic abnormalities and weaknesses as we learn more about the complex genetic tapestry that makes up each of us. This emphasis on

precision medicines has encouraged the pharmaceutical industry to engage in research and development, leading to a wide range of drugs that target the root of illnesses with previously unheard-of precision and efficacy.



After being mesmerised by these genomic insights, the pharmaceutical sector uncovers an extended canvas in the form of genetic data. Collaborations between genetic researchers and medication developers produce a rhythm that pinpoints possible therapeutic targets with unmatched accuracy. Clinical trials take on a remarkable quality when they are painstakingly planned with genetically stratified patient cohorts, ensuring that the appropriate medications are delivered to the right people at the right time.

Looking ahead, diagnostics stands out as a brilliant work of innovation that will change the course of the combat against illnesses. New opportunities for early identification and intervention are made possible by technological breakthroughs, pointing the way to a healthy future. Genetic testing at the point of treatment and liquid biopsies shines as rays of hope because they can detect illnesses before they show symptoms. Artificial intelligence (AI)-driven diagnostic algorithms provide a web of information, giving doctors predictive analytics to enable quick treatments and stop illnesses before they start.

Even said, we must not lose sight of the fact that this path involves constant ethical reflection and critical thought as we awe at this expanding piece of art. In addition to their brilliance, these interconnected worlds are beautiful because of the obligation to uphold ethical and scientific standards. As we advance, it is crucial to protect patient privacy, make sure that precision medicines are available and affordable, and understand the ethical issues around the use of genetic data.

"Converging Horizons" is a monument to human inventiveness, compassion, and a common goal for a better world in the vast tapestry of healthcare. The ability to change the fundamental nature of healthcare itself is contained inside this linked canvas, which is a living, breathing expression of hope and development. It urges us to imagine, create, and work together.

REFERENCES

[1] Ku, C. S., Loy, E. Y., Salim, A., Pawitan, Y., & Chia, K. S. (2010). The discovery of human genetic variations and their use as disease markers: past, present and future. *Journal of human genetics*, *55*(7), 403-415.
[2] Pollex, R. L., & Hegele, R. A. (2007). Copy number variation in the human genome and its implications for cardiovascular disease. *Circulation*, *115*(24), 3130-3138.
[3] Brown, S. M., Hay, J. G., & Ostrer, H. (2008). *Essentials of medical genomics*. John Wiley & Sons.
[4] Mattick, J. S., Dziadek, M. A., Terrill, B. N., Kaplan, W., Spigelman, A. D., Bowling, F. G., & Dinger, M. E. (2014). The impact of genomics on the future of medicine and health. *Medical Journal of Australia*, *201*(1), 17-20.

[5] https://www.med.unc.edu/ppmh/education/past-educational-offerings/explorations-in-genomic-medicine-research/
[6] Roth, S. C. (2019). What is genomic medicine?. *Journal of the Medical Library Association: JMLA*, *107*(3), 442.
[7] https://nap.nationalacademies.org/read/25277/chapter/2#5
[8] National Academies of Sciences, Engineering, and Medicine. (2018). *Understanding disparities in access to genomic medicine: proceedings of a workshop*. National Academies Press.
[9] Bauer, M. S., Damschroder, L., Hagedorn, H., Smith, J., & Kilbourne, A. M. (2015). An introduction to implementation science for the non-specialist. *BMC psychology*, *3*(1), 1-12.
[10] National Academies of Sciences, Engineering, and Medicine. (2016). Applying an implementation science approach to genomic medicine: workshop summary.
[11] Roberts, M. C., Clyne, M., Kennedy, A. E., Chambers, D. A., & Khoury, M. J. (2019). The current state of funded NIH grants in implementation science in genomic medicine: a portfolio analysis. *Genetics in Medicine*, *21*(5), 1218-1223.
[12] Implementation science and genomic medicine in action: A case study. Posted on September 18, 2019 by Mindy Clyne, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia [https://blogs.cdc.gov/genomics/2019/09/18/implementation-science-2/]
[13] https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/clinical-genomics
[14] https://www.nationalgeographic.com/science/article/partner-content-genomics-health-care
[15] Mattick, J. S., Dziadek, M. A., Terrill, B. N., Kaplan, W., Spigelman, A. D., Bowling, F. G., & Dinger, M. E. (2014). The impact of genomics on the future of medicine and health. *Medical Journal of Australia*, *201*(1), 17-20..
[16] Public health genomics. (2023, June 21). In *Wikipedia*. https://en.wikipedia.org/wiki/Public_health_genomics
[17] Khoury, M. J., Bowen, M. S., Clyne, M., Dotson, W. D., Gwinn, M. L., Green, R. F., ... & Yu, W. (2018). From public health genomics to precision public health: a 20-year journey. *Genetics in Medicine*, *20*(6), 574-582.
[18] Khoury, M. J., & Holt, K. E. (2021). The impact of genomics on precision public health: beyond the pandemic. *Genome medicine*, *13*(1), 67.
[19] https://www.med.unc.edu/ppmh/education/past-educational-offerings/explorations-in-genomic-medicine-research/
[20] https://orzuv.life/blog/precision-medicine-personalizing-healthcare-for-better-patient-outcomes
[21] Statista – The Statistics Portal. (n.d.). Statista. https://www.statista.com/aboutus/our-research-commitment/285/matej-mikulic
[22] Melissa Pistilli. (2023, July 10). Runner. https://investingnews.com/author/melissa-pestilli. Using Artificial Intelligence to Diagnose Rare Genetic Diseases - National Gaucher Foundation
[23] Parikh, J. R., Genetti, C. A., Aykanat, A., Brownstein, C. A., Schmitz-Abe, K., Danowski, M., Quitadomo, A., Madden, J. A., Yacoubian, C., Gain, R., Williams, T., Meskell, M., Brown, A., Frith, A., Rockowitz, S., Sliz, P., Agrawal, P. B., Defay, T., McDonagh, P., Reynders, J., … Beggs, A. H. (2021). A data-driven architecture using natural language processing to improve phenotyping efficiency and accelerate genetic diagnoses of rare disorders. HGG advances, 2(3), 100035. https://doi.org/10.1016/j.xhgg.2021.100035
[24] Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., Bhat, A. A., & Macha, M. A. (2022). Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular cancer, 21(1), 79. https://doi.org/10.1186/s12943-022-01543-7
[25] Mass spectrometry-based metabolomics in health and medical science: a systematic review. Xi-wu Zhang, Qiu-han Li, Zuo-di Xu, Jin-jin Dou (2020). RSC Advances.
[26] https://www.tomorrow.bio/post/what-is-biohacking-an-overview-of-the-growing-trend-2023-05-4450116062-biohacking
[27] https://www.forbes.com/sites/bernardmarr/2021/02/26/whats-biohacking-all-you-need-to-know-about-the-latest-health-craze/?sh=24a218845d76
[28] https://www.medicalnewstoday.com/articles/biohacking
[29] https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(18)30078-7
[30] https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(18)30078-7
[31] Chowdhury, Muhammad & Alzoubi, Khawla & Khandakar, Amith & Khalifa, Ridab & Abouhasera, Rayaan & Koubaa, Sirine & Ahmed, Rashid & Hasan, Anwarul. (2019). Wearable Real-Time Heart Attack Detection and Warning System to Reduce Road Accidents. Sensors. 19. 2780. 10.3390/s19122780.

[32] Pös, O., Budiš, J., & Szemes, T. (2019). Recent trends in prenatal genetic screening and testing. F1000Research, 8, F1000 Faculty Rev-764. https://doi.org/10.12688/f1000research.16837.1
[33] Xiao, S., Zhang, J., Zhu, Y., Zhang, Z., Cao, H., Xie, M., & Zhang, L. (2023). Application and Progress of Artificial Intelligence in Fetal Ultrasound. Journal of clinical medicine, 12(9), 3298. https://doi.org/10.3390/jcm12093298
[34] He, R., Liu, H., Fang, T., Niu, Y., Zhang, H., Han, F., Gao, B., Li, F., & Xu, F. (2021). A Colorimetric Dermal Tattoo Biosensor Fabricated by Microneedle Patch for Multiplexed Detection of Health-Related Biomarkers. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(24), e2103030. https://doi.org/10.1002/advs.202103030
[35] Liu, Q., Jin, X., Cheng, J., Zhou, H., Zhang, Y., & Dai, Y. (2023). Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). Molecular medicine reports, 27(5), 104. https://doi.org/10.3892/mmr.2023.12991
[36] Rabbani, B., Tekin, M. & Mahdieh, N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 59, 5–15 (2014). https://doi.org/10.1038/jhg.2013.114
[37] Hao, T., Huang, Z., Liang, L., Weng, H., & Tang, B. (2021). Health Natural Language Processing: Methodology Development and Applications. JMIR medical informatics, 9(10), e23898. https://doi.org/10.2196/23898
[38] Barberis, E., Khoso, S., Sica, A., Falasca, M., Gennari, A., Dondero, F., Afantitis, A., and Manfredi, M. 2022. “Precision Medicine Approaches with Metabolomics and Artificial Intelligence.” International Journal of Molecular Sciences 23 (19) (September 24): 11269. doi:10.3390/ijms231911269. http://dx.doi.org/10.3390/ijms231911269.
[39] Clish C. B. (2015). Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harbor molecular case studies, 1(1), a000588. https://doi.org/10.1101/mcs.a000588

